Login
$AMLX
$27.67 -$0.13 (0.47%) After hours

$AMLX SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Frates James M, Chief Financial Officer

Received 20,000 shares by exercise or conversion ($138K) · Sold 20,000 shares ($597K) · Received 20,000 shares by exercise or conversion ($138K) · 1 more

12 Nov 2026 Form 4: Klee Justin B., Director

Sold 100,000 shares ($2.98M)

12 Nov 2026 Form 4: Cohen Joshua B, Director

Sold 100,000 shares ($2.98M)

09 Nov 2026 144
09 Nov 2026 144
09 Nov 2026 144
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track

07 Oct 2026 Form 4: Milne George M Jr, Director

Sold 30,000 shares ($831K)

05 Oct 2026 144
14 Sep 2026 Form 4: Bedrosian Camille L, Chief Medical Officer

Sold 10,028 shares ($325K)

14 Sep 2026 Form 4: Frates James M, Chief Financial Officer

Sold 10,810 shares ($350K)

14 Sep 2026 Form 4: Mazzariello Gina, Chief Legal Officer

Sold 9,536 shares ($310K)

14 Sep 2026 Form 4: Klee Justin B., Director

Sold 30,464 shares ($980K)

14 Sep 2026 Form 4: Cohen Joshua B, Director

Sold 30,464 shares ($981K)

11 Sep 2026 144
11 Sep 2026 144
11 Sep 2026 144
11 Sep 2026 144
11 Sep 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support